The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20050561: McDATA Corporation; Computer Network Technology Corporation
20050530: Invitrogen Corporation; Dean Tsao
20050516: Value Creation Partners, Inc.; The J. M. Smucker Company
20050362: Humana Inc.; Miguel B. Fernandez
20050339: L-3 Communications Holdings, Inc.; The Boeing Company
20050018: Cemex, S.A. de C.V.; RMC Group p.l.c.
Letter To Commercial Alert Applying Commission Policy To Determine On A Case-By-Case Basis Whether Particular Advertising Formats Such As Product Placements Are Deceptive
Applying Commission Policy To Determine On A Case-By-Case Basis Whether Particular Advertising Formats Such As Product Placements Are Deceptive
20050542: Lindsay Goldberg & Bessemer L.P.; WestLB AG
20050541: Halifax Capital Partners, L.P.; Rinker Group Limited
20050533: Electro-Motive Diesel, Inc.; General Motors Corporation
0502006 Informal Interpretation
Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc.
20050563: Verizon Communications Inc.; St. Cloud Wireless Holdings, LLC
20050559: Mellon Financial Corporation; DPM Holdings, LLC
0502004 Informal Interpretation
0502005 Informal Interpretation
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
Genzyme Corporation and Ilex Oncology, Inc., In the Matter of
A consent order allowed Genzyme’s acquisition of ILEX Oncology, Inc., but requires the companies to divest certain assets in the market for solid organ transplant acute therapy drugs. Specifically, Genzyme is required to divest all contractual rights related to ILEX’s Campath®, an immunosuppressant antibody used in solid organ transplants to Schering AG.